Citation only
via Europe PMC
Sex as a major determinant of pro-longevity drug efficacy: a review of two decades of the NIA Interventions Testing Program.
Jiang N, Xu Z, Zhao S, Gelfond J, Strong R, Nelson JF.
The journals of gerontology. Series A, Biological sciences and medical sciences · 2025 · ▲ 1 citations
Abstract
Aging is the primary risk factor for frailty, sarcopenia, and functional decline, as well as cancer, cardiovascular and neurodegenerative diseases. Gaining insight into the biological mechanisms of aging could lead to interventions that broadly reduce age-related morbidity and mortality. To identify interventions that extend lifespan and delay aging, the National Institute on Aging launched the Interventions Testing Program (ITP) in 2004. This multi-site effort uses genetically heterogeneous UM-HET3 mice to evaluate the effects of candidate compounds. Over the past two decades, the ITP has tested 54 agents in more than 30, 000 mice. This is the first comprehensive review of the program's results, with particular emphasis on a striking pattern of sex-specific responses. By presenting the full scope of the findings, readers can better understand the overall impact of the program and easily access detailed information on specific drugs of interest. Notably, most compounds that extended lifespan were effective primarily or exclusively in male mice. Dosage and age of treatment onset influenced efficacy and were also sexually dimorphic. These sex differences suggest that mechanisms of aging are sexually dimorphic and highlight the importance of recognizing biological sex as a modifier of treatment efficacy. Investigating the basis for these differences should enable more targeted and effective geroprotective strategies for both sexes.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.1093/gerona/glaf138
- Canonical
- link ↗
- Fetched
- 2026-10-08 MST
Cite this
APA
N, J., Z, X., S, Z., J, G., R, S., & JF., N. (2025). Sex as a major determinant of pro-longevity drug efficacy: a review of two decades of the NIA Interventions Testing Program. <em>The journals of gerontology. Series A, Biological sciences and medical sciences</em>. https://doi.org/10.1093/gerona/glaf138
Vancouver
N J, Z X, S Z, J G, R S, JF. N. Sex as a major determinant of pro-longevity drug efficacy: a review of two decades of the NIA Interventions Testing Program. The journals of gerontology. Series A, Biological sciences and medical sciences. 2025. doi:10.1093/gerona/glaf138.
BibTeX
@article{jiang2025Sexasa,
title = {Sex as a major determinant of pro-longevity drug efficacy: a review of two decades of the NIA Interventions Testing Program.},
author = {Jiang N and Xu Z and Zhao S and Gelfond J and Strong R and Nelson JF.},
journal = {The journals of gerontology. Series A, Biological sciences and medical sciences},
year = {2025},
doi = {10.1093/gerona/glaf138},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
The Journals of Gerontology Series A 2025
Open access · OA
Sex as a major determinant of pro-longevity drug efficacy: a review of two decades of the NIA Interventions Testing Program
Elsevier eBooks 2015
Citation only
NIA Interventions Testing Program
Aging Cell 2014
Open access · CC-BY
Announcement
Ageing Research Reviews 2026
Open access · CC-BY
Sex differences in response to longevity interventions
Ageing research reviews 2026
Citation only
Sex differences in response to longevity interventions.
Aging Cell 2023
Open access · CC-BY